Shan X, Balakir R, Criado G, Wood J S, Seminario M C, Madrenas J, Wange R L
Laboratory of Cellular and Molecular Biology, National Institute on Aging, National Institutes of Health, Baltimore, Maryland 21224-6825, USA.
Mol Cell Biol. 2001 Nov;21(21):7137-49. doi: 10.1128/MCB.21.21.7137-7149.2001.
The tyrosine kinase ZAP-70 has been implicated as a critical intermediary between T-cell antigen receptor (TCR) stimulation and Erk activation on the basis of the ability of dominant negative ZAP-70 to inhibit TCR-stimulated Erk activation, and the reported inability of anti-CD3 antibodies to activate Erk in ZAP-70-negative Jurkat cells. However, Erk is activated in T cells receiving a partial agonist signal, despite failing to activate ZAP-70. This discrepancy led us to reanalyze the ZAP-70-negative Jurkat T-cell line P116 for its ability to support Erk activation in response to TCR/CD3 stimulation. Erk was activated by CD3 cross-linking in P116 cells. However, this response required a higher concentration of anti-CD3 antibody and was delayed and transient compared to that in Jurkat T cells. Activation of Raf-1 and MEK-1 was coincident with Erk activation. Remarkably, the time course of Ras activation was comparable in the two cell lines, despite proceeding in the absence of LAT tyrosine phosphorylation in the P116 cells. CD3 stimulation of P116 cells also induced tyrosine phosphorylation of phospholipase C-gamma1 (PLCgamma1) and increased the intracellular Ca(2+) concentration. Protein kinase C (PKC) inhibitors blocked CD3-stimulated Erk activation in P116 cells, while parental Jurkat cells were refractory to PKC inhibition. The physiologic relevance of these signaling events is further supported by the finding of PLCgamma1 tyrosine phosphorylation, Erk activation, and CD69 upregulation in P116 cells on stimulation with superantigen and antigen-presenting cells. These results demonstrate the existence of two pathways leading to TCR-stimulated Erk activation in Jurkat T cells: a ZAP-70-independent pathway requiring PKC and a ZAP-70-dependent pathway that is PKC independent.
基于显性负性ZAP-70抑制T细胞抗原受体(TCR)刺激的Erk激活的能力,以及报道的抗CD3抗体无法在ZAP-70阴性的Jurkat细胞中激活Erk,酪氨酸激酶ZAP-70被认为是TCR刺激与Erk激活之间的关键中间体。然而,尽管未能激活ZAP-70,但在接受部分激动剂信号的T细胞中Erk仍被激活。这种差异促使我们重新分析ZAP-70阴性的Jurkat T细胞系P116对TCR/CD3刺激的反应中支持Erk激活的能力。在P116细胞中,CD3交联可激活Erk。然而,与Jurkat T细胞相比,这种反应需要更高浓度的抗CD3抗体,且延迟且短暂。Raf-1和MEK-1的激活与Erk激活同时发生。值得注意的是,尽管P116细胞中LAT酪氨酸磷酸化不存在,但两种细胞系中Ras激活的时间进程相当。P116细胞的CD3刺激也诱导了磷脂酶C-γ1(PLCγ1)的酪氨酸磷酸化,并增加了细胞内Ca(2+)浓度。蛋白激酶C(PKC)抑制剂可阻断P116细胞中CD3刺激的Erk激活,而亲本Jurkat细胞对PKC抑制具有抗性。超抗原和抗原呈递细胞刺激P116细胞时,PLCγ1酪氨酸磷酸化、Erk激活和CD69上调的发现进一步支持了这些信号事件的生理相关性。这些结果表明,在Jurkat T细胞中存在两条导致TCR刺激的Erk激活的途径:一条不依赖ZAP-70的途径需要PKC,另一条依赖ZAP-70的途径不依赖PKC。